US OptionsDetailed Quotes
PFE250103C27000
- 0.01
- 0.000.00%
15min DelayClose Jan 3 16:00 ET
0.00High0.00Low
0.00Open0.01Pre Close0 Volume35.26K Open Interest27.00Strike Price0.00Turnover0.00%IV3.84%PremiumJan 3, 2025Expiry Date0.00Intrinsic Value100Multiplier-18DDays to Expiry0.01Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2601.00Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Pfizer Stock Discussion
Pfizer has completed a secondary offering of 700 million Haleon ordinary shares at 357 pence (approximately $4.36) per share on January 17, 2025. The sale was executed through a block trade agreement with multiple financial institutions including J.P. Morgan Securities, Morgan Stanley, HSBC, and others.
Following the transaction, Pfizer now holds 661,709,764 Haleon ordinary shares, representing approximately 7.3% of Haleon's outstanding shares. This includes 197,228,952 restric...
Full year earnings release on 04 Feb 2025. Waiting for good results
Takeda-backed Ascentage Pharma Group (AAPG) (OTCPK:ASPHF), which is developing treatments for blood cancer, has set terms for a $170M U.S. initial public offering.
In an SEC filing, Ascentage (AAPG) said it plans to offer 7.3M American Depositary Shares, representing 29.3M ordinary shares. While the company didn't disclose a price range, it indicated in its filing fee schedule it was looking to raise around $170M.
The company hopes to list its shares on Nasdaq under the symbol A...
Go Go Go!!! I will wait for u at $50 finishing line
Perhaps not as serious, but biomedical industry definitely will benefit if they're able to come up with some immunity boosters or even antidote to such outbreak.
Anyway just sharing my POVs, feel free to share yours!
No comment yet